Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Titel:
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial
Auteur:
Randon, Giovanni Lonardi, Sara Fassan, Matteo Palermo, Federica Tamberi, Stefano Giommoni, Elisa Ceccon, Carlotta Di Donato, Samantha Fornaro, Lorenzo Brunetti, Oronzo De Vita, Ferdinando Bittoni, Alessandro Chini, Claudio Spallanzani, Andrea Nappo, Floriana Bethaz, Valerie Strippoli, Antonia Latiano, Tiziana Cardellino, Giovanni Gerardo Giuliani, Francesco Morano, Federica Niger, Monica Raimondi, Alessandra Prisciandaro, Michele Pircher, Chiara Carlotta Sciortino, Carolina Marchesi, Silvia Garattini, Silvio Ken AirĂ², Giulia Miceli, Rosalba Di Bartolomeo, Maria Pietrantonio, Filippo